(Press-News.org) SAN DIEGO — A study comparing how physicians discuss clinical trials during clinical interactions with black patients versus white patients further confirms racial disparities in the quality of communication between physicians and patients.
Oncologists provided black patients with less information overall about cancer clinical trials compared with white patients, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.
"Minority patients tend to receive less information, which could, in part, explain under-enrollment by minorities in clinical cancer trials," said Susan Eggly, Ph.D., associate professor of oncology in the Population Studies and Disparities Program at Wayne State University School of Medicine and the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. "These disparities could also lead to minority patients being enrolled in trials without fully understanding the purpose of the trial and the potential risks of participation."
Eggly and colleagues examined 22 video-recorded interactions between oncologists and patients during which a clinical trial was offered. Patients were matched by cancer type and sociodemographic characteristics. Half of the video-recorded interactions were with black patients and the other half were with white patients. Researchers used linguistic discourse analytical methods to examine several aspects of the interactions, including overall discussion of clinical trials and the five basic elements of consent: purpose, risks, benefits, alternatives to participating and the voluntary nature of trial participation.
Data revealed that clinical trial interactions with black patients were shorter overall and included less discussion of clinical trials compared with interactions with white patients. Key aspects of consent were also discussed less with black patients than with white patients, especially the purpose of the trial and risks of participation. However, the researchers found that oncologists spoke more about voluntary participation with black patients than with white patients.
Previous research by Eggly and colleagues showed that black patients tended to ask fewer questions and they trusted their doctors less than white patients did. In addition, physician biases affected the quality of communication, which Eggly believes may also account for the differences found in this study.
"Taking a close look at interactions and the language used can help us to identify patterns of behavior and make the necessary improvements that may ultimately lead to decisions that are in the best interest of each patient," she said.
###
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.
A disparity of words: A comparison of offers to participate in cancer clinical trials by patient race. Susan Eggly1, Ellen Barton2, Andrew Winckles2, Louis A. Penner1, Terrance L. Albrecht1. 1Wayne State University/Karmanos Cancer Institute, Detroit, MI, 2Wayne State University, Detroit, MI.
Purpose: Oncologist-patient communication clearly influences patients' decisions about participating in clinical trials (Albrecht 2008; Eggly 2008). Black-White differences in the quality of patient-physician communication exist in oncology interactions (Eggly 2011), but no prior study has used real-time data from actual clinical interactions to investigate whether there are also Black-White differences in communication about clinical trials. The purpose of this study was to compare communication during offers to participate in cancer clinical trials in oncology visits with Black and with White patients.
Patients and Methods: Data were taken from an archive of 47 transcribed, video recorded oncology interactions that included the explicit offer of a cancer clinical trial (Albrecht 2008). All visits with Black patients (n=11) were identified and matched with a sample of visits with White patients (n=11). We used linguistic discourse analysis to analyze the visits (n=22) with specific focus on discussions of clinical trials and the five basic elements of consent (purpose, risks and benefits of the trial, alternatives to participating, and the voluntary nature of trial participation). We used word count as an objective measure of the amount of actual face-to-face discussion that occurred during the visits. We assessed Black-White differences in word count of the entire visits; the number of times clinical trials or any of the elements of consent were mentioned by oncologists, patients, or patients' companions; and word count of discussions during mentions of each of these topics.
Results: Mean word count of the entire visit was less for Black than White patients (m=4877.73Blacks vs. 7247.18Whites, d=.8740). Clinical trials were mentioned less frequently during visits with Black than White patients (M=2.73Blacks vs. 4.27Whites, d=1.2099). Mean word count during mentions of clinical trials was also less for Black patients (1089.64Blacks vs. 1867.09Whites, d=1.0618). Regarding the elements of consent, mean word count was less for Black patients during discussions of purpose (M=90.91 Blacks vs. 181.22 Whites, d=.9272) and risks (M=211.900Blacks vs. 390.27Whites, d=.6477). Risks were also mentioned less frequently for Black patients (M=1.91Blacks vs. 3.18Whites, d=.5782). However, voluntary participation was mentioned more frequently (M=2.18Blacks vs. 1.55Whites, d=.4139) for White than Black patients.
Conclusion: Black patients, as compared to White patients, may make decisions about clinical trial participation based on less overall discussion with oncologists and less discussion of the purpose and risks of participation. One possible explanation is a less active communication style of Black patients in medical visits, which has been shown in other research (Gordon 2006; Eggly 2011). Other possibilities include oncologist concerns about patient mistrust and/or nonconscious racial bias (van Ryn 2011). Possible communicative strategies to overcome these disparities include more conscious attention to mentioning and developing the topic of clinical trials with Black patients, with particular attention to the purpose and risks of trial participation.
Black patients received less clinical trial information than white patients
2012-10-29
ELSE PRESS RELEASES FROM THIS DATE:
Women in less affluent areas of Chicago less likely to reside near mammography facility
2012-10-29
SAN DIEGO — Women in socioeconomically disadvantaged and less affluent areas of Chicago were less likely to live near a mammography facility with various aspects of care compared with women in less socioeconomically disadvantaged and more affluent areas. This finding could be a contributing factor to the association between disadvantaged areas and late-stage breast cancer diagnosis, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.
"Other research has found that women living in disadvantaged ...
Associations linking weight to breast cancer survival vary by race/ethnicity
2012-10-29
SAN DIEGO — An extreme body mass index or high waist-to-hip ratio, both measures of body fat, increased risk for mortality among patients with breast cancer, but this association varied by race/ethnicity, according to recently presented data.
Marilyn L. Kwan, Ph.D., a research scientist in the Kaiser Permanente Northern California Division of Research in Oakland, Calif., presented these results at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.
Prior research has shown racial/ethnic differences in survival after a ...
Minorities most likely to have aggressive tumors, less likely to get radiation
2012-10-29
SAN DIEGO — Women with aggressive breast cancer were more likely to receive adjuvant chemotherapy, but at the expense of completing locoregional radiation therapy, according to recently presented data. This was especially true in minorities, who were the most likely to present with moderate- to high-grade and symptomatically detected tumors.
"Radiation treatment decreases the risk for breast cancer recurring and improves survival from the disease," said Abigail Silva, M.P.H., Susan G. Komen Cancer Disparities Research trainee at the University of Illinois in Chicago, ...
Language, immigration status of hispanic caregivers impacted care of children with cancer
2012-10-29
SAN DIEGO — Language barriers and the immigration status of caregivers appear to impact the care of Hispanic children with cancer and affect the experience of the families within the medical system, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.
"Ensuring good communication with patients and their families is as important as the actual therapy we give, regardless of what language is spoken," said Mark Fluchel, M.D., assistant professor in the department of pediatrics, division of hematology-oncology ...
Researchers look beyond space and time to cope with quantum theory
2012-10-29
Physicists have proposed an experiment that could force us to make a choice between extremes to describe the behaviour of the Universe.
The proposal comes from an international team of researchers from Switzerland, Belgium, Spain and Singapore, and is published today in Nature Physics. It is based on what the researchers call a 'hidden influence inequality'. This exposes how quantum predictions challenge our best understanding about the nature of space and time, Einstein's theory of relativity.
"We are interested in whether we can explain the funky phenomena we observe ...
NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer
2012-10-29
Researchers have identified several genes that are linked to one of the most lethal forms of uterine cancer, serous endometrial cancer. The researchers describe how three of the genes found in the study are frequently altered in the disease, suggesting that the genes drive the development of tumors. The findings appear in the Oct. 28, 2012, advance online issue of Nature Genetics. The team was led by researchers from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health.
Cancer of the uterine lining, or endometrium, is the most ...
Key discovered to how chemotherapy drug causes heart failure
2012-10-29
HOUSTON - Doxorubicin, a 50-year-old chemotherapy drug still in widespread use against a variety of cancers, has long been known to destroy heart tissue, as well as tumors, in some patients.
Scientists have identified an unexpected mechanism via the enzyme Top2b that drives the drug's attack on heart muscle, providing a new approach for identifying patients who can safely tolerate doxorubicin and for developing new drugs. A team led by scientists at The University of Texas MD Anderson Cancer Center reports its findings about the general DNA-damaging drug today in the ...
How to make stem cells – nuclear reprogramming moves a step forward
2012-10-29
The idea of taking a mature cell and removing its identity (nuclear reprogramming) so that it can then become any kind of cell, holds great promise for repairing damaged tissue or replacing bone marrow after chemotherapy. Hot on the heels of his recent Nobel prize Dr John B. Gurdon has published today in BioMed Central's open access journal Epigenetics & Chromatin research showing that histone H3.3 deposited by the histone-interacting protein HIRA is a key step in reverting nuclei to a pluripotent type, capable of being any one of many cell types.
All of an individual's ...
US shale gas drives up coal exports
2012-10-29
US CO2 emissions from domestic energy have declined by 8.6% since a peak in 2005, the equivalent of 1.4% per year.
However, the researchers warn that more than half of the recent emissions reductions in the power sector may be displaced overseas by the trade in coal.
Dr John Broderick, lead author on the report from the Tyndall Centre for Climate Change Research, comments: "Research papers and newspaper column inches have focussed on the relative emissions from coal and gas.
"However, it is the total quantity of CO2 from the energy system that matters to the climate. ...
Atrial fibrillation is a 'modifiable' risk factor for stroke
2012-10-29
Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.(1) These therapies have been improved in the past few years by the introduction of new anticoagulant drugs, such that AF - like high blood pressure or smoking - may now be considered a "modifiable" risk factor for stroke, whose treatment can reduce the degree of risk.
Professor ...